Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

    Get Diamond plan for FREE

    logo

    Venus Concept Inc. (VERO)

    Price:

    2.45 USD

    ( + 0.02 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    VERO
    Name
    Venus Concept Inc.
    Industry
    Medical - Devices
    Sector
    Healthcare
    Price
    2.450
    Market Cap
    4.555M
    Enterprise value
    41.691M
    Currency
    USD
    Ceo
    Rajiv Kanishka Liyanaarchchie De Silva
    Full Time Employees
    292
    Ipo Date
    2017-10-12
    City
    Toronto
    Address
    235 Yorkland Boulevard

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    Establishment Labs Holdings Inc.

    VALUE SCORE:

    3

    Symbol
    ESTA
    Market Cap
    1.264B
    Industry
    Medical - Devices
    Sector
    Healthcare

    2nd position

    PROCEPT BioRobotics Corporation

    VALUE SCORE:

    9

    Symbol
    PRCT
    Market Cap
    2.294B
    Industry
    Medical - Devices
    Sector
    Healthcare

    The best

    Viemed Healthcare, Inc.

    VALUE SCORE:

    11

    Symbol
    VMD
    Market Cap
    283.524M
    Industry
    Medical - Devices
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    -0.086
    P/S
    0.076
    P/B
    1.536
    Debt/Equity
    15.927
    EV/FCF
    -1.998
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    0.628
    Earnings yield
    -11.564
    Debt/assets
    0.587
    FUNDAMENTALS
    Net debt/ebidta
    -1.027
    Interest coverage
    -5.871
    Research And Developement To Revenue
    0.101
    Intangile to total assets
    0.052
    Capex to operating cash flow
    -0.015
    Capex to revenue
    0.005
    Capex to depreciation
    0.071
    Return on tangible assets
    -0.691
    Debt to market cap
    8.137
    Piotroski Score
    4.000
    FUNDAMENTALS
    PEG
    0.006
    P/CF
    -0.192
    P/FCF
    -0.241
    RoA %
    -65.523
    RoIC %
    -77.390
    Gross Profit Margin %
    64.878
    Quick Ratio
    0.711
    Current Ratio
    1.097
    Net Profit Margin %
    -68.769
    Net-Net
    -24.848
    FUNDAMENTALS PER SHARE
    FCF per share
    -12.945
    Revenue per share
    41.197
    Net income per share
    -28.331
    Operating cash flow per share
    -12.758
    Free cash flow per share
    -12.945
    Cash per share
    2.658
    Book value per share
    1.900
    Tangible book value per share
    -0.328
    Shareholders equity per share
    1.595
    Interest debt per share
    29.184
    TECHNICAL
    52 weeks high
    14.500
    52 weeks low
    2.100
    Current trading session High
    2.465
    Current trading session Low
    2.350
    DIVIDEND
    Dividend yield
    0.00%
    Payout ratio
    0.00%
    Years of div. Increase
    0
    Years of div.
    0
    Q-shift
    Dividend per share
    0
    SIMILAR COMPANIES
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.002
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -4.932
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.537
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.235
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -2.885
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -6.325
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.000
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.445
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    -0.012685526%
    P/E
    -4.881
    DESCRIPTION

    Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes aesthetic device platforms, including Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; and Venus Viva, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss, a device for non-invasive lipolysis of the abdomen and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; and ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles. The company is headquartered in Toronto, Canada.

    NEWS
    https://images.financialmodelingprep.com/news/venus-concept-inc-vero-q2-2025-earnings-call-transcript-20250814.jpg
    Venus Concept Inc. (VERO) Q2 2025 Earnings Call Transcript

    seekingalpha.com

    2025-08-14 20:06:34

    Venus Concept Inc. (NASDAQ:VERO ) Q2 2025 Earnings Conference Call August 14, 2025 5:00 PM ET Company Participants Domenic Della Penna - Executive VP & CFO Rajiv Kanishka Liyanaarchchie De Silva - CEO & Director Operator Good day, ladies and gentlemen, and welcome to the Second Quarter 2025 Earnings Conference Call for Venus Concept Inc. [Operator Instructions] Please note that this conference call is being recorded and that the recording will be available on the company's website for replay. Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward- looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including those identified in the Risk Factors section of our most recent annual report on Form 10-K filed with the Securities and Exchange Commission.

    https://images.financialmodelingprep.com/news/venus-concept-announces-second-quarter-2025-financial-results-20250814.jpg
    Venus Concept Announces Second Quarter 2025 Financial Results

    globenewswire.com

    2025-08-14 16:05:00

    TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and six months ended June 30, 2025.

    https://images.financialmodelingprep.com/news/venus-concept-to-release-second-quarter-of-fiscal-year-20250716.jpg
    Venus Concept to Release Second Quarter of Fiscal Year 2025 Financial Results on August 14, 2025

    globenewswire.com

    2025-07-16 07:30:00

    TORONTO, July 16, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that second quarter of fiscal year 2025 financial results will be released after the market closes on Thursday, August 14, 2025.

    https://images.financialmodelingprep.com/news/venus-concept-announces-65-million-debttoequity-exchange-transaction-20250701.jpg
    Venus Concept Announces $6.5 Million Debt-to-Equity Exchange Transaction

    globenewswire.com

    2025-07-01 16:05:00

    Further reduction of outstanding debt by Madryn Asset Management improves the Company's balance sheet position Further reduction of outstanding debt by Madryn Asset Management improves the Company's balance sheet position

    https://images.financialmodelingprep.com/news/venus-concept-announces-closing-of-up-to-345-million-20250609.jpg
    Venus Concept Announces Closing of Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

    globenewswire.com

    2025-06-09 16:05:00

    $1.15 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the exercise in full of unregistered short-term warrants $1.15 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the exercise in full of unregistered short-term warrants

    https://images.financialmodelingprep.com/news/venus-concept-announces-up-to-345-million-registered-direct-20250606.jpg
    Venus Concept Announces Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

    globenewswire.com

    2025-06-06 11:35:00

    $1.15 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the exercise in full of unregistered short-term warrants $1.15 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the exercise in full of unregistered short-term warrants

    https://images.financialmodelingprep.com/news/venus-concept-announces-definitive-agreement-to-sell-venus-hair-20250606.jpg
    Venus Concept Announces Definitive Agreement to Sell Venus Hair Business for $20 Million

    globenewswire.com

    2025-06-06 07:30:00

    TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today it has entered into a definitive agreement to sell its Venus Hair business to MHG Co. Ltd (“Meta Healthcare Group”) in an all-cash transaction valued at $20 million, subject to a customary working capital adjustment. The net proceeds from the transaction, once completed, will enhance the Company's balance sheet and financial condition and provide valuable capital to fund strategic growth initiatives.

    https://images.financialmodelingprep.com/news/venus-concept-inc-vero-q1-2025-earnings-call-transcript-20250515.jpg
    Venus Concept Inc. (VERO) Q1 2025 Earnings Call Transcript

    seekingalpha.com

    2025-05-15 10:50:29

    Venus Concept Inc. (NASDAQ:VERO ) Q1 2025 Earnings Conference Call May 15, 2025 8:00 AM ET Company Participants Rajiv De Silva - CEO Domenic Della Penna - CFO Conference Call Participants Thomas McGovern - Maxim Group Operator Good day, ladies and gentlemen, and welcome to the First Quarter 2025 Earnings Conference Call for Venus Concept Inc. At this time all participants have been placed in a listen-only mode. Please note that this conference call is being recorded and that the recording will be available on the company's website for replay.

    https://images.financialmodelingprep.com/news/venus-concept-raises-a-total-of-approximately-27-million-20250414.jpg
    Venus Concept Raises a Total of Approximately $2.7 Million in Gross Proceeds from Previously Announced Registered Direct Offerings of Common Stock

    globenewswire.com

    2025-04-14 16:05:00

    TORONTO, April 14, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 386,700 shares of common stock at a purchase price of $4.06 per share.

    https://images.financialmodelingprep.com/news/venus-concept-announces-15-million-registered-direct-offering-of-20250411.jpg
    Venus Concept Announces $1.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

    globenewswire.com

    2025-04-11 08:02:00

    TORONTO, April 11, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has entered into definitive agreements for the purchase and sale of 386,700 shares of common stock at a purchase price of $4.06 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about April 14, 2025, subject to the satisfaction of customary closing conditions.

    https://images.financialmodelingprep.com/news/venus-concept-announces-closing-of-11-million-registered-direct-20250410.jpg
    Venus Concept Announces Closing of $1.1 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

    globenewswire.com

    2025-04-10 16:05:00

    TORONTO, April 10, 2025 (GLOBE NEWSWIRE) --  Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 328,573 shares of common stock at a purchase price of $3.50 per share.

    https://images.financialmodelingprep.com/news/venus-concept-announces-11-million-registered-direct-offering-of-20250409.jpg
    Venus Concept Announces $1.1 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

    globenewswire.com

    2025-04-09 16:35:00

    TORONTO, April 09, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has entered into definitive agreements for the purchase and sale of 328,573 shares of common stock at a purchase price of $3.50 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about April 10, 2025, subject to the satisfaction of customary closing conditions.

    https://images.financialmodelingprep.com/news/venus-concept-to-release-first-quarter-of-fiscal-year-20250407.jpg
    Venus Concept to Release First Quarter of Fiscal Year 2025 Financial Results on May 15, 2025

    globenewswire.com

    2025-04-07 07:30:00

    TORONTO, April 07, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that first quarter of fiscal year 2025 financial results will be released before the market opens on Thursday, May 15, 2025.

    https://images.financialmodelingprep.com/news/venus-concept-announces-11-million-debttoequity-exchange-transaction-20250401.jpg
    Venus Concept Announces $11 million Debt-to-Equity Exchange Transaction

    globenewswire.com

    2025-04-01 16:45:00

    Continued improvement of the Company's financial position through additional reduction of outstanding debt by Madryn Asset Management Continued improvement of the Company's financial position through additional reduction of outstanding debt by Madryn Asset Management

    https://images.financialmodelingprep.com/news/venus-concept-inc-vero-q4-2024-earnings-conference-call-20250331.jpg
    Venus Concept Inc. (VERO) Q4 2024 Earnings Conference Call Transcript

    seekingalpha.com

    2025-03-31 11:39:18

    Venus Concept Inc. (NASDAQ:VERO ) Q4 2024 Earnings Conference Call March 31, 2025 8:00 AM ET Company Participants Rajiv De Silva - CEO Domenic Della Penna - EVP and CFO Conference Call Participants Marie Thibault - BTIG Jeremy Pearlman - Maxim Group Operator Good day, ladies and gentlemen, and welcome to the Fourth Quarter and Fiscal Year 2024 Earnings Conference Call for Venus Concept Inc. At this time, all participants have been placed in a listen-only mode. Please note that this conference call is being recorded and that the recording will be available on the company's website for replay.

    https://images.financialmodelingprep.com/news/venus-concept-announces-fourth-quarter-and-fiscal-year-2024-20250331.jpg
    Venus Concept Announces Fourth Quarter and Fiscal Year 2024 Financial Results

    globenewswire.com

    2025-03-31 07:00:00

    TORONTO, March 31, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and twelve months ended December 31, 2024.